First Tracks Biotherapeutics (TRAX) — Long-term Investment Intensity
First Tracks Biotherapeutics (TRAX) has a Long-term Investment Intensity of 8.0% as of December 2024. Long-term investments of $35.47 Million represent 8.0% of total assets of $441.89 Million. A higher ratio indicates a company with significant capital committed to long-duration strategic positions. For the complete balance sheet picture, see how large is First Tracks Biotherapeutics's balance sheet.
LT Investment Intensity
Long-term Investments
Total Assets
Country
First Tracks Biotherapeutics Long-term Investment Intensity (2023–2024)
This chart shows how First Tracks Biotherapeutics's Long-term Investment Intensity has evolved across 2 annual periods from 2023 to 2024. As of December 2024, the intensity stands at 8.0%, reflecting long-term investments of $35.47 Million against total assets of $441.89 Million USD. See First Tracks Biotherapeutics working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
Annual Long-term Investment Intensity for First Tracks Biotherapeutics (2023–2024)
The table below presents the year-by-year Long-term Investment Intensity for First Tracks Biotherapeutics from 2023 to 2024, covering 2 annual filings. Each row shows total assets, long-term investments, the intensity percentage, and the change in percentage points compared to the prior year. Read debt load of First Tracks Biotherapeutics for a breakdown of total debt and financial obligations.
| Year | LT Investment Intensity | LT Investments (USD) | Total Assets | Change (pp) |
|---|---|---|---|---|
| 2024 | 8.0% | $35.47 Million | $441.89 Million | ▲ +1.9 pp |
| 2023 | 6.1% | $27.03 Million | $444.11 Million | — |